Risk of acute promyelocytic leukemia in multiple sclerosis: Coding variants of DNA repair genes

Neurology

Volumn 76, Issue 12, 2011, Pages 1059-1065

  Hasan, S K ^a,b,c   Buttari, F ^b,c   Ottone, T ^a,c   Voso, M T ^d   Hohaus, S ^d   Marasco, E ^e   Mantovani, V ^e   Garagnani, P ^e   Sanz, M A ^f   Cicconi, L ^a,c   Bernardi, G ^b,c   Centonze, D ^b,c   Lo Coco, F ^a,b,c  

^a Clinica Neurologica   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; MITOXANTRONE; NIBRIN; NUCLEAR PROTEIN; PREDNISONE; PROTEIN LIG 4; UNCLASSIFIED DRUG; XRCC5 PROTEIN;

ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG DETOXIFICATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC DAMAGE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79953199080     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318211c3c8     Document Type: Article

References (28)

1. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol 2010;9:299-308.
2. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74:1463-1470.
3. Pascual AM, Tellez N, Bosca I, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler 2009;15:1303-1310.
4. Hasan SK, Mays AN, Ottone T, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008;112:3383-3390.
5. Hasan SK, Ottone T, Schlenk RF, et al. Analysis of t(15; 17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci. Genes Chromosomes Cancer 2010;49:726-732.
6. Rivera-Munoz P, Malivert L, Derdouch S, et al. DNA repair and the immune system: From V(D)J recombination to aging lymphocytes. Eur J Immunol 2007;37(suppl 1): S71-S82. (Pubitemid 350131270)
7. Fishel ML, Vasko MR, Kelley MR. DNA repair in neurons: so if they don't divide what's to repair? Mutat Res 2007;614:24-36. (Pubitemid 44920332)
8. Seedhouse C, Russell N. Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br J Haematol 2007;137:513-529. (Pubitemid 46817341)
9. Casorelli I, Tenedini E, Tagliafico E, et al. Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: focus on DNA repair genes. Leukemia 2006;20:1978-1988. (Pubitemid 44614887)
10. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-846. (Pubitemid 41746873)
11. Ruttan CC, Glickman BW. Coding variants in human double-strand break DNA repair genes. Mutat Res 2002; 509:175-200. (Pubitemid 35341460)
12. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-442. (Pubitemid 38443646)
13. Ghalie RG, Mauch E, Edan G, et al. A study of therapyrelated acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002;8:441-445.
14. Voso MT, Fabiani E, D'Alo F, et al. Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol 2007;18:1523-1528. (Pubitemid 47365486)
15. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176-13181. (Pubitemid 28509544)
16. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2003;42:299-305. (Pubitemid 38054375)
17. Boulton SJ, Jackson SP. Components of the Kudependent non-homologous end-joining pathway are involved in telomeric length maintenance and telomeric silencing. EMBO J 1998;17:1819-1828. (Pubitemid 28119135)
18. Jones IM, Thomas CB, Xi T, Mohrenweiser HW, Nelson DO. Exploration of methods to identify polymorphisms associated with variation in DNA repair capacity phenotypes. Mutat Res 2007;616:213-220. (Pubitemid 46198862)
19. Shin A, Lee KM, Ahn B, et al. Genotype-phenotype relationship between DNA repair gene genetic polymorphisms and DNA repair capacity. Asian Pac J Cancer Prev 2008;9: 501-505.
20. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-2808. (Pubitemid 38638843)
21. D'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 2008; 8: 512-522. (Pubitemid 351881854)
22. Knight JA, Skol AD, Shinde A, et al. Genome-wide association study to identify novel loci associated with therapyrelated myeloid leukemia susceptibility. Blood 2009;113: 5575-5582.
23. Nickoloff JA, De Haro LP, Wray J, Hromas R. Mechanisms of leukemia translocations. Curr Opin Hematol 2008;15:338-345.
24. Huber LJ, Yang TW, Sarkisian CJ, Master SR, Deng CX, Chodosh LA. Impaired DNA damage response in cells expressing an exon 11-deleted murine Brca1 variant that localizes to nuclear foci. Mol Cell Biol 2001;21:4005-4015. (Pubitemid 32476462)
25. Lovelock PK, Healey S, Au W, et al. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 2006;43:74-83. (Pubitemid 43102586)
26. Scardocci A, Guidi F, D'Alo F, et al. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer 2006;95:1108-1113. (Pubitemid 44606840)
27. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multi drug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-3762. (Pubitemid 43739516)
28. Cotte S, von Ahsen N, Kruse N, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 2009;132:2517-2530.